Abstract
Despite 25 years of ADHD pharmacogenetic studies, there are few reliable predictors to guide treatment. The dopamine transporter (DAT1) is a primary pharmacodynamic target for methylphenidate (MPH) with known genetic variation hypothesized to impact response, while CYP2D6 variation impacts atomoxetine (ATX) kinetics. We examined genetic variation in DAT1 and CYP2D6 with dose response in youth diagnosed with ADHD exposed to both medications.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of the American Academy of Child & Adolescent Psychiatry
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
